BiomX Inc. (PHGE) is a pre-revenue clinical-stage biological products company with a liquidation posture that is deeply negative and structurally deteriorating. As of December 31, 2025, total assets are $5.78M against total liabilities of $7.09M (current $6.38M plus noncurrent $0.71M), producing reported stockholders' equity of negative $1.30M. Under liquidation haircuts, the recovery picture is worse: cash and equivalents of $4.36M recover at par; restricted cash of $0.60M recovers at par; money market funds of $3.08M (classified within AssetsFairValueDisclosure) recover at par; other current assets of $0.56M recover at roughly 90%; and noncurrent assets of $0.21M recover near zero. Gross PP&E of $5.59M is substantially depreciated ($5.43M accumulated depreciation), leaving net book value of approximately $0.16M, which at a 50-60% liquidation haircut yields minimal recovery. Intangibles associated with the APT asset acquisition (IPR&D) carried an impairment charge of $11.84M in the period and are assigned zero liquidation value. The full asset-side recovery is therefore approximately $5.0-5.5M against liabilities held at face value of approximately $7.1M, yielding a negative equity recovery of approximately $1.5-2.0M, consistent with MFFAIS's reported CLV/LLV/OLV of negative $2.0M. The primary liquidity risk driver is operating cash burn: net cash used in operations was $26.39M for FY2025, while net loss was $36.20M. The company raised $13.19M in financing activities, primarily through warrant proceeds ($4.53M) and pre-funded warrant exercises. Cash balance at year-end was $4.36M, which at FY2025 burn rates represents roughly two months of operating runway. The Israeli subsidiary BiomX Israel filed for insolvency in December 2025 and was deconsolidated as of February 4, 2026 following court-appointed trustee action. Management stated no significant value is expected to be recovered from BiomX Israel. Post-period transactions (all occurring after December 31, 2025) substantially altered the entity's structure: the entire prior management and board resigned by March 2026 and were replaced; the company acquired Zorro Net Ltd. from Water IO Ltd. (an affiliate of director Yeganeh's T3 Defense connection) for 1.3M shares plus a $1.25M promissory note due July 2026; and it acquired 60% of DR. Frucht Systems Ltd. from Mandragola Ltd. for $750K cash, a $3.0M convertible note at 9% due 2029, 923K shares, pre-funded warrants for 923K shares, and five-year warrants for 3.69M shares at $12.00. These acquisitions are not reflected in the December 31, 2025 balance sheet but represent significant post-period liabilities and dilution. The Mandragola note ($3.0M) and the Zorro net note ($1.25M) together add $4.25M in face-value obligations accruing post-period. Filing discusses BiomX Israel's insolvency and deconsolidation in MD&A footnotes but the deconsolidated subsidiary's balance sheet items are not separately tagged in XBRL. The 2026 Equity Incentive Plan authorizing 1.39M additional shares and a December 2025 Series Y Preferred Stock private placement ($3.0M, converted to common in March 2026) further complicate the capital structure. Related-party concentration is high: two 5%-plus stockholders (Water IO Ltd. at 12.86% and Mandragola Ltd. at 9.13%) are counterparties to the post-period acquisitions, and the director overseeing those transactions (Yeganeh) is affiliated with both. Severance obligations to the prior management team were partially pre-funded in March 2025 (three months' salary each) and remaining balances reduced remaining non-statutory entitlements; full settlement costs for all three resigned officers are not separately tagged in XBRL.
▼ Community Notes